secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001104659-25-026854
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma: TXM shows positive H5N1 data in non-human primates; FDA meeting planned H1 2025
--------------------------------------------------------------------------------

- Single-dose TXM (480 mg) reduced lung viremia below quantitation vs up to 1x10^7 in controls after H5N1 challenge.
- TXM-treated NHPs maintained stable weight vs 4.2% loss in controls (p<0.004).
- Consistent efficacy across NHPs, ferrets (increased survival), and mice (complete survival, undetectable viremia).
- Company plans FDA meeting in H1 2025 to discuss accelerated approval under the Animal Rule.
- Investor event on March 31, 2025 at 10:00 AM ET to present TXM overview and next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925026854/0001104659-25-026854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925026854/tm2510102d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer